Loading organizations...
§ Private Profile · Menlo Park, CA, USA
A medical device technology company developing tools for interventional procedures and minimally invasive treatments.
iScience Interventional is a technology company focused on developing advanced medical devices for interventional procedures, specializing in innovative tools designed to explore, illuminate, and deliver therapies in minimally invasive treatments. Their product development pipeline targets critical needs within the medical device sector, likely encompassing areas such as ophthalmology or interventional cardiology, where leadership expertise is concentrated. The company aims to enhance patient outcomes and procedural efficiency through novel approaches to diagnostics and therapeutic delivery. While specific financial metrics, such as funding raised or valuation, are not publicly disclosed, the organization operates within a competitive landscape of medical technology innovators. Co-founder, President, CEO, and Director Mike Nash guides the company's strategic direction and product development initiatives. Its business model centers on unknown.
iScience Interventional has raised $36.0M across 2 funding rounds.
iScience Interventional has raised $36.0M in total across 2 funding rounds.
iScience Interventional has raised $36.0M across 2 funding rounds. Most recently, it raised $21.0M Series F in May 2009.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2009 | $21M Series F | — | — | Announced |
| Apr 1, 2003 | $15M Series C | — | — | Announced |
iScience Interventional has raised $36.0M in total across 2 funding rounds.
iScience Interventional is a medical technology company specializing in microcatheter and imaging technologies for interventional ophthalmology. It develops tools that enable ophthalmologists to deliver site-specific therapies to treat conditions like glaucoma and retinal diseases, targeting the suprachoroidal and subretinal spaces to reduce intraocular pressure (IOP) or administer drugs and biologics precisely.[1][2][3][4][5]
The company serves ophthalmologists and patients with moderate to advanced glaucoma and sight-threatening retinal conditions, solving the problem of imprecise drug delivery in the eye by providing advanced catheter-based systems for targeted interventions. Backed by investors including Medtronic, Johnson & Johnson Development Corp., and others, it focuses on accelerating commercialization of these innovations.[1]
iScience Interventional emerged as a developer of specialized ocular technologies, with leadership including Michael F. Nash as president and CEO, who highlighted the company's alignment with evolving ophthalmology needs during a key investment from Medtronic.[1] The firm has attracted significant venture backing from investors such as Asset Management Co., Prism VentureWorks, DeNovo Ventures, Three Arch Partners, Affinity Capital Management, CHV Capital Inc., L Capital, and Sightline Partners, signaling early traction in the medtech space.[1]
A pivotal moment came with Medtronic's investment, aimed at supporting development and commercialization of eye drug-delivery tech, amid rapid changes in ophthalmology toward interventional approaches. This funding enabled acceleration of clinical trials and market entry for therapies addressing glaucoma and retinal diseases.[1]
iScience Interventional rides the trend of interventional ophthalmology, shifting from systemic or broad ocular treatments to precise, catheter-guided therapies amid rising demand for glaucoma and retinal disease management.[1][2][3][4][5] Timing aligns with advances in biologics and imaging, where traditional drops or injections fall short, fueled by aging populations and medtech convergence with pharma.
Market forces like investor interest from giants (Medtronic, J&J) amplify its influence, fostering ecosystem growth in ocular drug delivery and potentially standardizing site-specific interventions.[1] It contributes by bridging device innovation with clinical needs, influencing how ophthalmology integrates minimally invasive tech.
iScience is poised to expand its pipeline through accelerated commercialization, leveraging Medtronic's support for broader adoption in glaucoma and retinal therapies.[1] Trends like biologics integration and AI-enhanced imaging will shape its path, potentially capturing share in a market hungry for precise ocular solutions.
Its influence may evolve by setting standards for interventional eye tech, tying back to its core mission of enabling ophthalmologists to explore, illuminate, and deliver transformative treatments.[3][5]